Migalastat · Galafold

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Fabry Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
JP
  • Treatment of Fabry disease in patients with GLA mutations categorized as amenable to treatment with migalastat
Product first approved 2018PMDA
CA
  • GALAFOLD (migalastat capsules) is indicated for: • long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease [deficiency of α-galactosidase (α-Gal A)] and who have an α-Gal A mutation determined to be amenable by an in vitro assay (see 10.1 Mechanism of Action - Table 5).
Product first approved 2017Health Canada
EU
  • Galafold is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation (see the tables in section 5.1).
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Fabry Disease
NCT06904261 · Amicus Therapeutics
2026-01-08 – 2028-12 · Fabry Disease
What this study did
NCT02194985 · Amicus Therapeutics
2015-03-14 – 2019-10-23 · Fabry Disease
What this study did
NCT01458119 · Amicus Therapeutics
2011-10-14 – 2016-02-17 · Fabry Disease
What this study did
Phase 2 (6)
Fabry Disease
NCT01196871 · Amicus Therapeutics
2011-02-02 – 2012-10-09 · Fabry Disease
What this study did
NCT00526071 · Amicus Therapeutics
2007-09-17 – 2012-09-08 · Fabry Disease
What this study did
NCT00283959 · Amicus Therapeutics
2006-06-27 – 2008-05-08 · Fabry Disease
What this study did
NCT00283933 · Amicus Therapeutics
2006-05-09 – 2008-03-12 · Fabry Disease
What this study did
NCT00214500 · Amicus Therapeutics
2006-01-02 – 2008-01-29 · Fabry Disease
What this study did
Phase 1 (5)
Fabry Disease
NCT02082327 · Amicus Therapeutics
2014-03 – 2014-06 · Fabry Disease
What this study did
NCT01730469 · Amicus Therapeutics
2011-08 – 2012-04 · Fabry Disease
What this study did
NCT01489995 · Amicus Therapeutics
2011-10 – 2011-12 · Fabry Disease
What this study did
NCT01730482 · Amicus Therapeutics
2011-08 – 2011-09 · Fabry Disease
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Fabry Disease
NCT05280548 · Sanofi
2022-05-03 – 2027-12-06 · Fabry Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Migalastat (Galafold): this drugApprovedSmall moleculeAlpha-galactosidase A (GLA / α-Gal A)Partial signal
NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed
Agalsidase Beta (Fabrazyme)ApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks).
NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase.
Pegunigalsidase AlfaApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505)
Isaralgagene CivaparvovecPhase 1/2Gene therapy / editingAlpha-galactosidase A (GLA / α-Gal A)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Galafold (Migalastat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Fabry DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT04020055 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Phase 3Fabry DiseaseRecruiting
Est. primary completion 2027-12 · NCT06904261 · CT.gov ↗
What to watch

See the full readout calendar ↗